RE:RE:RE:RE:Dream. PMN needs will know that the beta-amyloid hypothesis is not a dead issue. FDA approval of aducanumab will set that straight by approving aducanumab. If that is the case, Biogen will go to the market.
That will open it up for PMN. PMN will partner up with a BP ( competitor to Biogen) to fund the clinical trials and move forward from that point.
jmo
G1945V